A Phase I Trial of PVSRIPO for Patients With Unresectable Melanoma
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Lerapolturev (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Istari Oncology
Most Recent Events
- 06 Sep 2024 Status changed from completed to discontinued.
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 25 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.